Zhejiang Chimin Pharm Co Ltd (SHG:603222) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Chimin Pharm Co Ltd (603222)
Zhejiang Chimin Pharm Co Ltd (SHG:603222) has a market capitalization of $753.01 Million (CN¥5.15 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #10464 globally and #3051 in its home market, demonstrating a -4.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Chimin Pharm Co Ltd's stock price CN¥9.80 by its total outstanding shares 525090615 (525.09 Million). Analyse Zhejiang Chimin Pharm Co Ltd (603222) cash conversion ratio to see how efficiently the company converts income to cash.
Zhejiang Chimin Pharm Co Ltd Market Cap History: 2015 to 2026
Zhejiang Chimin Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.04 Billion to $753.01 Million (0.35% CAGR).
Zhejiang Chimin Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Chimin Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.67x
Zhejiang Chimin Pharm Co Ltd's market cap is 0.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.04 Billion | $448.60 Million | $51.75 Million | 2.31x | 20.06x |
| 2016 | $1.00 Billion | $450.38 Million | $40.89 Million | 2.23x | 24.51x |
| 2017 | $797.14 Million | $602.90 Million | $52.88 Million | 1.32x | 15.07x |
| 2018 | $736.62 Million | $697.83 Million | $32.06 Million | 1.06x | 22.97x |
| 2019 | $2.98 Billion | $771.28 Million | $69.20 Million | 3.87x | 43.14x |
| 2020 | $734.55 Million | $877.64 Million | -$6.93 Million | 0.84x | N/A |
| 2021 | $999.69 Million | $1.10 Billion | $147.52 Million | 0.91x | 6.78x |
| 2022 | $671.16 Million | $837.24 Million | $26.13 Million | 0.80x | 25.68x |
| 2023 | $615.47 Million | $894.51 Million | -$65.48 Million | 0.69x | N/A |
| 2024 | $521.73 Million | $775.73 Million | -$59.71 Million | 0.67x | N/A |
Competitor Companies of 603222 by Market Capitalization
Companies near Zhejiang Chimin Pharm Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Zhejiang Chimin Pharm Co Ltd by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #136 globally with a market cap of $162.57 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #250 globally with a market cap of $98.12 Billion USD ( €83.93 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #274 globally with a market cap of $93.24 Billion USD ( €79.76 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #523 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #136 | Intuitive Surgical Inc | NASDAQ:ISRG | $162.57 Billion | $457.78 |
| #250 | EssilorLuxottica S. A. | PA:EL | $98.12 Billion | €181.25 |
| #274 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $93.24 Billion | €88.50 |
| #523 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Zhejiang Chimin Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Chimin Pharm Co Ltd's market cap moved from $1.04 Billion to $ 753.01 Million, with a yearly change of 0.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥753.01 Million | +7.34% |
| 2025 | CN¥701.52 Million | +34.46% |
| 2024 | CN¥521.73 Million | -15.23% |
| 2023 | CN¥615.47 Million | -8.30% |
| 2022 | CN¥671.16 Million | -32.86% |
| 2021 | CN¥999.69 Million | +36.10% |
| 2020 | CN¥734.55 Million | -75.39% |
| 2019 | CN¥2.98 Billion | +305.21% |
| 2018 | CN¥736.62 Million | -7.59% |
| 2017 | CN¥797.14 Million | -20.45% |
| 2016 | CN¥1.00 Billion | -3.46% |
| 2015 | CN¥1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Zhejiang Chimin Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $753.01 Million USD |
| MoneyControl | $753.01 Million USD |
| MarketWatch | $753.01 Million USD |
| marketcap.company | $753.01 Million USD |
| Reuters | $753.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Chimin Pharm Co Ltd
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms. It also offers medical instruments, in… Read more